Skip to main content

New story in Health from Time: FDA Issues Warning About Hydroxychloroquine for COVID-19



On April 24, the U.S. Food and Drug Administration (FDA) issued a MedWatch Safety Alert about the use of hydroxychloroquine or chloroquine for treating COVID-19.

After preliminary studies hinted that hydroxychloroquine may help some patients with severe COVID-19 symptoms to improve, the FDA issued an emergency use authorization (EUA) to allow doctors to use the drug on hospitalized patients whose symptoms are not improving. Several studies were also launched to study its effects as a COVID-19 treatment.

However, hydroxychloroquine can have negative effects on the heart, contributing to abnormal heart rhythms that can be life-threatening. For those with existing heart problems, the dangers could be even greater, especially if the drug is combined with the antibiotic azithromycin, as some researchers treating COVID-19 patients have done. The American Heart Association, the American College of Cardiology and the Heart Rhythm Society jointly published cautionary guidelines recommending that doctors stop using hydroxychloroquine on patients at any sign of heart trouble.

The drugs are approved for treating malaria, and in the case of hydroxychloroquine, also for treating autoimmune disorders like rheumatoid arthritis and lupus. (In the U.S., hydroxychloroquine is more common since the malaria parasite is largely resistant to chloroquine.) For people taking the drug for an autoimmune disorder, their doctors monitor for signs of adverse heart events and can adjust dosage as needed.

The FDA’s safety alert doesn’t say those patients should stop taking the drugs they need, but instead warns general consumers to “not buy these medicines from online pharmacies without a prescription from your health care professional.” The alert stresses that hydroxychloroquine and chloroquine “should be used for COVID-19 only where patients can be appropriately monitored in the hospital as required by the EUA or are enrolled in a clinical trial with appropriate screening and monitoring.”

The FDA says that neither drug has been proven safe and effective in treating COVID-19. In fact, a study published on April 23 involving 368 COVID-19 patients at U.S. Veterans Health Administration hospitals found that taking hydroxychloroquine alone, or in combination with azithromycin, did not reduce the need for a ventilator compared to those not taking the drugs. Further, people taking hydroxychloroquine alone had a higher risk of dying during the study than those not taking the drug. Researchers in China came to a similar conclusion in a study of 150 COVID-19 patients randomly assigned to receive hydroxychloroquine or the current standard of care: after a month, both groups had similar symptom profiles, and showed similar levels of the virus, suggesting that the drug wasn’t clearing the COVID-19 virus in a significant way.

The National Institutes of Health is conducting an ongoing study of hydroxychloroquine among hospitalized patients, as is Novartis, whose Sandoz division makes a generic version of the drug.

Labels:

Popular posts from this blog

New story in Health from Time: COVID-19 Has Been ‘Apocalyptic’ for Public Transit. Will Congress Offer More Help?

While trying to get to work over the past few months, Brittany Williams, a Seattle home care worker, has often been passed by two or three buses before one stops to let her board. Buses in her area that once carried anywhere from about 50 to 100 passengers have been limited to between 12 and 18 to prevent overcrowding in response to coronavirus, and Williams’ commute, typically a half-hour ride, now takes more than double that time. Other Seattle transit riders have described budgeting as much as an extra hour per trip to account for the reduced capacity, eating into their time at work, school or with family. Even with the ridership limits in place, Williams, 34, doesn’t feel safe on public transit. Some passengers don’t wear face coverings, and bus drivers sometimes ignore capacity limits, she says. On one ride with her seven-year-old son, she decided to get off at a stop far from her home after a driver allowed a crowd of people to board. “It’s very trying. I’ll put...
Read more

New story in Health from Time: A Montana Care Home Refused Free COVID-19 Tests. Now, Nearly Every Resident Has Coronavirus

(BILLINGS, Mont.) — It was meant to be a last line of defense to protect the most vulnerable as the coronavirus spread across the United States : Montana officials offered free testing in May for staff and residents at assisted living and long-term care facilities. But not all of them followed through, according to state data, including a facility in Billings, Montana’s largest city, that cares for people with dementia and other memory problems. The virus has infected almost every resident and killed eight, accounting for almost a quarter of Montana’s 34 confirmed deaths. Thirty-six employees also have tested positive at the facility where 59 people lived before the deaths began. Read more: ‘It’s Getting Worse.’ Nursing Home Workers Confront Risks in Facilities Devastated by Coronavirus While Montana’s rates of confirmed infections and deaths are much lower than other parts of the country, the outbreak at Canyon Creek Memory Care illustrates that even the most simple an...
Read more

New story in Health from Time: An At-Home Coronavirus Test May Be On the Way in the U.S.

As cases of COVID-19 continue to climb in the U.S. , there’s a new urgency to make sure there are as many tests as possible to diagnose people who have symptoms that might indicate an infection. Knowing if people are positive is important for guiding their next steps: self-isolation, avoiding contact with others, and, if their symptoms get worse, seeking medical care. To date, access to tests has been spotty at best across the country, and while more kits are now available than even a week ago , most are gene-based assays that take several days for commercial labs to process and produce results. That may change in about two months if the Food and Drug Administration (FDA) gives Emergency Use Authorization to the first blood-based COVID-19 test in the U.S. Scanwell Health, an at-home test company based in California, licensed the rights to a test developed by Chinese company Innovita, which was used extensively at the height of country’s epidemic earlier this year. “The ...
Read more